Drugs / ALN-PNP
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06024408 | May 2024 → Jul 2025 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05648214 | Dec 2022 → Aug 2027 expected | metabolic dysfunction-associated steatotic liver disease | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07527910 | May 2026 → Mar 2030 expected | metabolic dysfunction-associated steatotic liver disease | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-PNP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07527910 ↗ |
| Action | Inhibit | “ALN-PNP reduces the amount of Patatin-like phospholipase domain-containing protein 3 (PNPLA3), a protein that liver cells make” NCT07527910 ↗ |
| Modality | Small interfering RNA (siRNA) | “ALN-PNP, an siRNA Targeting PNPLA3” NCT05648214 ↗ |
| Route | Subcutaneous | “Administered as single subcutaneous (SC) injection on day 1” NCT06024408 ↗ |
| Target | PNPLA3 | “ALN-PNP, an siRNA Targeting PNPLA3” NCT05648214 ↗ |